M&A activity of pharma CMOs will continue despite challenging borrowing environment, says GlobalData
CMOs showed an increasing reluctance to take on debt in 2022
CMOs showed an increasing reluctance to take on debt in 2022
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
Subscribe To Our Newsletter & Stay Updated